Cargando…

Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model

AIM: To determine a dose response relationship of disintegration of a hyaluronic acid (HA) and hyaluronidase (HAS) used in prostate cancer radiotherapy. MATERIALS AND METHODS: Five in-vitro models are applicated with 3 ml (ml) HA. For dissolution varying doses of HAS were used: 6 ml, 3 ml, 1.5 ml, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanneste, Ben G.L., Lutgens, Ludy, Van Limbergen, Evert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749177/
https://www.ncbi.nlm.nih.gov/pubmed/35036588
http://dx.doi.org/10.1016/j.ctro.2021.12.009
_version_ 1784631171950313472
author Vanneste, Ben G.L.
Lutgens, Ludy
Van Limbergen, Evert J.
author_facet Vanneste, Ben G.L.
Lutgens, Ludy
Van Limbergen, Evert J.
author_sort Vanneste, Ben G.L.
collection PubMed
description AIM: To determine a dose response relationship of disintegration of a hyaluronic acid (HA) and hyaluronidase (HAS) used in prostate cancer radiotherapy. MATERIALS AND METHODS: Five in-vitro models are applicated with 3 ml (ml) HA. For dissolution varying doses of HAS were used: 6 ml, 3 ml, 1.5 ml, and 0 ml. One ml contains 150 International Units (IU). Each HAS was added with saline till the complementary amount of 6 ml. One phantom was solely implanted with a HA 3 ml acting as a control. Length, width and height were measured on different time points: 1st day 4 times, 2nd day 3 times, third day 2 times, and then once daily during one week, with a final measurement 2 weeks after implantation. The experiments were performed in duplicate to exclude variations and confirm the results. RESULTS: The fastest dissolution was observed with the highest concentration of HAS, already observed at the first time point 2 h after implantation, with volume decrease of 50% on the second day, and less than 1 ml residue (33%) on day 4. The 2 other concentrations of HAS also showed a volume decrease, with less than 2 ml (66%) on day 4. All the applied quantities of HAS are observed with a residue of less than 1 ml after 7 days. After 14 days the control phantom and the saline filled one remains on steady state volume (3 ml). CONCLUSIONS: A dose response was observed by HAS injection: highest volumes of HAS dissolute most swiftly. Using a ratio of HA:HAS of 1:2 results in a decrease to half of initial volume within 24 h. This is of special interest when used in clinical practice following erroneous positioning, and dissolution is urgently needed.
format Online
Article
Text
id pubmed-8749177
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87491772022-01-13 Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model Vanneste, Ben G.L. Lutgens, Ludy Van Limbergen, Evert J. Clin Transl Radiat Oncol Technical Note AIM: To determine a dose response relationship of disintegration of a hyaluronic acid (HA) and hyaluronidase (HAS) used in prostate cancer radiotherapy. MATERIALS AND METHODS: Five in-vitro models are applicated with 3 ml (ml) HA. For dissolution varying doses of HAS were used: 6 ml, 3 ml, 1.5 ml, and 0 ml. One ml contains 150 International Units (IU). Each HAS was added with saline till the complementary amount of 6 ml. One phantom was solely implanted with a HA 3 ml acting as a control. Length, width and height were measured on different time points: 1st day 4 times, 2nd day 3 times, third day 2 times, and then once daily during one week, with a final measurement 2 weeks after implantation. The experiments were performed in duplicate to exclude variations and confirm the results. RESULTS: The fastest dissolution was observed with the highest concentration of HAS, already observed at the first time point 2 h after implantation, with volume decrease of 50% on the second day, and less than 1 ml residue (33%) on day 4. The 2 other concentrations of HAS also showed a volume decrease, with less than 2 ml (66%) on day 4. All the applied quantities of HAS are observed with a residue of less than 1 ml after 7 days. After 14 days the control phantom and the saline filled one remains on steady state volume (3 ml). CONCLUSIONS: A dose response was observed by HAS injection: highest volumes of HAS dissolute most swiftly. Using a ratio of HA:HAS of 1:2 results in a decrease to half of initial volume within 24 h. This is of special interest when used in clinical practice following erroneous positioning, and dissolution is urgently needed. Elsevier 2022-01-05 /pmc/articles/PMC8749177/ /pubmed/35036588 http://dx.doi.org/10.1016/j.ctro.2021.12.009 Text en © 2022 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Technical Note
Vanneste, Ben G.L.
Lutgens, Ludy
Van Limbergen, Evert J.
Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model
title Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model
title_full Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model
title_fullStr Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model
title_full_unstemmed Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model
title_short Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model
title_sort evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model
topic Technical Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749177/
https://www.ncbi.nlm.nih.gov/pubmed/35036588
http://dx.doi.org/10.1016/j.ctro.2021.12.009
work_keys_str_mv AT vannestebengl evaluationofhyaluronicacidgeldissolutionwithhyaluronidaseinaninvitroprostatecancermodel
AT lutgensludy evaluationofhyaluronicacidgeldissolutionwithhyaluronidaseinaninvitroprostatecancermodel
AT vanlimbergenevertj evaluationofhyaluronicacidgeldissolutionwithhyaluronidaseinaninvitroprostatecancermodel